A peer-reviewed study published in npj Antimicrobials and Resistance has demonstrated that Ask Eolas, an AI-powered clinical decision support system developed by Eolas Medical, achieved 100% prescribing accuracy in a randomized controlled trial conducted by researchers at Imperial College London, with support from the NIHR Northwest London Patient Safety Research Collaboration. The findings highlight the potential of AI to address the U.S. antibiotic crisis, where the CDC reports that up to 50% of antibiotics prescribed in hospitals are unnecessary or inappropriate, contributing to over 2.8 million antibiotic-resistant infections and 35,000 deaths annually.
The study evaluated three tools across progressively complex prescribing scenarios involving 45 clinicians: Hospital PDF Guidelines (47% accuracy), the Eolas App (60%), and Ask Eolas (100%). The improvement was statistically significant (p < 0.001). The absolute risk reduction was 53% compared to standard PDF guidelines, with a number needed to treat (NNT) of 1.9 — meaning for every two clinicians using Ask Eolas, one additional prescribing error was prevented.
Clinicians using Ask Eolas also reported substantially higher prescribing confidence and lower cognitive workload across all NASA Task Load Index domains, a standardized cognitive workload assessment. The system allows clinicians to ask questions in natural language and receive answers drawn exclusively from their health system’s own approved guidelines and protocols, with full source references, improving clinician access and adherence to hospital-developed protocols at the point of care.
Eolas Medical is already deployed across several leading U.S. health systems and academic medical centers including Mass General Brigham, Stanford, and Boston Children’s Hospital, and is expanding antimicrobial stewardship capabilities nationwide. The company recently opened its U.S. headquarters in Cambridge, Massachusetts, and continues to build out its team to expand its reach across the U.S. market.
“This study demonstrates how guideline-grounded AI can strengthen antimicrobial stewardship infrastructure while supporting frontline clinicians in high-pressure environments. With the opening of our U.S. headquarters in Cambridge, Massachusetts, we are firmly committed to making this technology available to health systems across the country, because every clinician deserves real-time access to the best evidence at the point of care,” said Dr. Declan Kelly, Founder & CEO of Eolas Medical.
Learn more at www.eolasmedical.com. Read the full study here.
